GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CSPC Pharmaceutical Group 1093.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

8.43

-0.24%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥29.49bn

FY2016FY2025

Net income

CN¥4.40bn

FY2016FY2025

Free cash flow

CN¥4.64bn

FY2016FY2025

Shareholders' equity

CN¥38.63bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥29.49bnCN¥29.54bnCN¥36.63bnCN¥31.59bnCN¥31.90bnCN¥27.45bnCN¥22.63bnCN¥21.48bnCN¥15.18bnCN¥12.89bn
Gross profitCN¥19.34bnCN¥20.67bnCN¥25.83bnCN¥22.73bnCN¥24.19bnCN¥20.56bnCN¥16.29bnCN¥14.26bnCN¥9.18bnCN¥6.58bn
Research and developmentCN¥6.59bnCN¥5.29bnCN¥5.63bnCN¥4.07bnCN¥3.93bnCN¥3.18bnCN¥2.05bnCN¥1.62bnCN¥800.5mCN¥420.3m
Operating incomeCN¥4.50bnCN¥5.49bnCN¥8.18bnCN¥6.96bnCN¥7.16bnCN¥5.99bnCN¥4.59bnCN¥4.40bnCN¥3.45bnCN¥2.72bn
Net incomeCN¥4.40bnCN¥4.41bnCN¥6.84bnCN¥6.22bnCN¥6.42bnCN¥5.68bnCN¥3.80bnCN¥3.73bnCN¥2.72bnCN¥2.19bn
Diluted earnings per share0.380.380.580.520.540.470.320.310.230.19

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥54.38bnCN¥51.63bnCN¥53.87bnCN¥47.93bnCN¥40.36bnCN¥34.91bnCN¥30.18bnCN¥30.76bnCN¥20.95bnCN¥17.18bn
Cash and short-term investmentsCN¥10.32bnCN¥9.02bnCN¥15.24bnCN¥16.15bnCN¥12.49bnCN¥10.25bnCN¥6.93bnCN¥6.95bnCN¥6.48bnCN¥3.77bn
Total liabilitiesCN¥14.15bnCN¥12.24bnCN¥13.11bnCN¥11.71bnCN¥9.21bnCN¥8.11bnCN¥7.62bnCN¥10.19bnCN¥5.97bnCN¥5.32bn
DebtCN¥746.2mCN¥507.3mCN¥706.9mCN¥582.5mCN¥94.0mCN¥316.7mCN¥187.5mCN¥70.6mCN¥884.0mCN¥1.02bn
Shareholders' equityCN¥38.63bnCN¥37.53bnCN¥38.65bnCN¥34.65bnCN¥30.19bnCN¥25.93bnCN¥21.17bnCN¥19.94bnCN¥15.15bnCN¥11.76bn
Shares outstanding11,520m11,638m11,852m11,933m11,952m11,955m11,955m11,983m11,764m11,631m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥6.86bnCN¥4.53bnCN¥4.86bnCN¥9.43bnCN¥5.40bnCN¥7.52bnCN¥4.50bnCN¥5.23bnCN¥3.20bnCN¥3.04bn
Capital spending−CN¥2.22bn−CN¥2.52bn−CN¥2.20bn−CN¥3.03bn−CN¥2.05bn−CN¥1.71bn−CN¥2.39bn−CN¥2.53bn−CN¥1.19bn−CN¥1.24bn
Free cash flowCN¥4.64bnCN¥2.02bnCN¥2.66bnCN¥6.40bnCN¥3.35bnCN¥5.81bnCN¥2.11bnCN¥2.70bnCN¥2.01bnCN¥1.80bn
Dividends paid−CN¥2.83bn−CN¥3.29bn−CN¥3.17bn−CN¥2.44bn−CN¥1.94bn−CN¥1.50bn−CN¥1.12bn−CN¥1.04bn−CN¥845.6m−CN¥756.8m

Financial ratios

Data as of 10 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin65.6%70.0%70.5%71.9%75.8%74.9%
Operating margin15.3%18.6%22.3%22.0%22.4%21.8%
Net margin14.9%14.9%18.7%19.7%20.1%20.7%
Return on equity11.4%13.7%17.7%20.9%21.3%21.9%
Return on assets8.1%9.9%12.7%15.1%15.9%16.3%
Free cash flow yield7.7%6.9%5.8%10.2%6.1%7.6%
Revenue growth-14.2%-6.1%-0.4%15.3%16.2%21.3%
Earnings growth-14.2%-25.0%-5.5%12.8%13.0%49.3%
Current ratio2.19x2.27x2.63x2.67x2.81x2.53x
Debt to equity0.01x0.01x0.02x0.01x0.00x0.02x
Equity ratio71.0%72.7%71.7%72.3%74.8%74.3%
Interest coverage102.89x125.82x271.52x279.45x802.40x421.00x
R&D as a share of sales22.3%17.9%15.4%12.9%12.3%11.6%
Buybacks as a share of market value1.0%1.8%0.7%0.2%0.0%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.3%1.4%10.3%
Operating income-13.5%-5.6%8.2%
Net income-10.9%-5.0%10.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin67.8%69.6%71.5%68.4%
Operating margin16.9%19.8%20.5%20.6%
Net margin14.9%17.2%18.2%17.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings19.411.111.113.813.914.726.816.631.320.1
Price to sales2.91.72.12.72.83.04.52.95.63.4

Dividends and splits

Per share, in the currency the company pays

Paid for 13 years. Last went ex-dividend on 24 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.150.240.340.250.200.170.1420.094
  • 8-for-5 split · 15 Oct 2020
  • 6-for-5 split · 18 Jun 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.